Abstract
Aim: We retrospectively evaluated the effect of dabrafenib/trametinib combination in patients with BRAF-mutated non-small-cell lung cancer (NSCLC) treated in a single center from 2017 to 2022.Patients: The response and safety data of 42 patients (27 treated in first-line and 15 as second/subsequent lines) were analyzed.Results: The objective response was 73.8%, with no differences between patients undergoing first- or second-line. A longer, statistically significant median progression-free survival (PFS) was observed in patients receiving the combination in first-line vs those in the second/subsequent lines (19.9 months [95% CI: 19.7-20] vs 13.1 months [95% CI: 8.6-17.6], respectively; p = 0.012). The median overall survival (OS) was 29.9 months (95% CI: 14.1-45.7) for patients treated with the combination in first-line and 22.4 months (95% CI: 14.6-30.2) for those treated in subsequent lines. The combination was well toleratedConclusion: We confirm the efficacy of dabrafenib/trametinib in BRAF-V600-mutated NSCLC.
Keywords:
BRAF mutation; NSCLC; drug combination; efficacy; real life.
Plain language summary
[Box: see text].
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
-
Carcinoma, Non-Small-Cell Lung* / drug therapy
-
Carcinoma, Non-Small-Cell Lung* / genetics
-
Carcinoma, Non-Small-Cell Lung* / mortality
-
Carcinoma, Non-Small-Cell Lung* / pathology
-
Female
-
Humans
-
Imidazoles* / administration & dosage
-
Imidazoles* / adverse effects
-
Imidazoles* / therapeutic use
-
Lung Neoplasms* / drug therapy
-
Lung Neoplasms* / genetics
-
Lung Neoplasms* / mortality
-
Lung Neoplasms* / pathology
-
Male
-
Middle Aged
-
Mutation*
-
Oximes* / administration & dosage
-
Oximes* / adverse effects
-
Oximes* / therapeutic use
-
Progression-Free Survival
-
Proto-Oncogene Proteins B-raf* / genetics
-
Pyridones* / administration & dosage
-
Pyridones* / adverse effects
-
Pyridones* / therapeutic use
-
Pyrimidinones* / administration & dosage
-
Pyrimidinones* / adverse effects
-
Pyrimidinones* / therapeutic use
-
Retrospective Studies
Substances
-
Proto-Oncogene Proteins B-raf
-
dabrafenib
-
Imidazoles
-
Oximes
-
trametinib
-
BRAF protein, human
-
Pyridones
-
Pyrimidinones